Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

CHEMBIO DIAGNOSTIC SYSTEMS

Chembio develops, manufactures and commercializes diagnostic solutions and products for the rapid and early detection... read more Featured Products: More products

Download Mobile App





Chembio Diagnostics Showcases New DPP Line of Rapid Tests at MEDICA 2019

By LabMedica International staff writers
Posted on 19 Nov 2019
Chembio Diagnostics (Medford, NY, USA) showcased its new DPP line of rapid tests, including DPP Syphilis Screen and Confirm; DPP HIV 1-2 Screen; and, for the global market, DPP Syphilis/HIV combo, the MEDICA 2019 International Trade Fair on November 18-21 in Düsseldorf, Germany. More...
In addition, the company presented its legacy product line of HIV 1-2 SURE CHECK, HIV 1-2 STAT-PAK, HIV 1-2 STAT-PAK Dipstick, as well as its line of unique animal TB diagnostic products.

The MEDICA is the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals. The event drew over 6,000 exhibitors from 70 countries and 120,000 trade visitors from over 170 countries.

Chembio is a leading Point-of-Care (POC) diagnostics company that focuses on detecting and diagnosing infectious diseases. The company’s patented DPP technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in approximately 15 minutes.

At the 2019 edition of MEDICA, Chembio showcased its DPP Syphilis Screen and Confirm Assay (CE Marked), a rapid POC test that simultaneously and separately detects treponemal and nontreponemal antibodies. Since it screens and confirms syphilis infection simultaneously, there is no need for reflex testing and it does not require specialized medical training. It provides results in as little as 15 minutes, enabling physicians to make treatment decisions, while reducing overtreatment rate and cost burden by eliminating repeated visits to healthcare professionals.

Chembio also showcased its DPP HIV 1-2 Screen Assay, a CLIA-waived test for the rapid detection of HIV 1 and HIV 2 antibodies in oral fluid and all blood matrices. It is intended for use as a POC test to aid in the diagnosis of infection with HIV 1 and HIV 2 and is suitable for use in multi-test algorithms that have been established in many countries or as a standalone initial test. For the global market, Chembio showcased its DPP Syphilis/HIV Combo Assay, the first dual HIV 1/2 and Syphilis POC test based on its DPP technology platform. It is a single-use, immunochromatographic, rapid test for the detection of antibodies to Human Immunodeficiency Virus Types 1 and 2 (HIV 1/2) and Treponema pallidum (the causative agent of syphilis) in fingerstick whole blood, venous whole blood, serum, and plasma. A unique feature of this kit is Chembio’s new DPP SampleTainer bottle which contains a pre-measured dilution buffer within a closed vial that also serves as a dropper for performing the assay.

In addition, Chembio showcased its legacy product line, including HIV 1-2 SURE CHECK, a unique, easy-to-use, self-contained, single-use collection and testing device for the rapid, visual detection of antibodies to HIV 1 and HIV 2; HIV 1-2 STAT-PAK, which are easy-to-perform, single-use diagnostic tests for the rapid (15 minutes), visual detection of antibodies to HIV 1 and HIV 2 at POC; and HIV 1-2 STAT-PAK Dipstick, which are easy-to-perform, single-use diagnostic tests for the rapid, visual detection of antibodies to HIV 1 and HIV 2.

Related Links:
Chembio Diagnostics


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated PCR System
OnePCR
New
PSA Assay
CanAg PSA EIA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.